You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 95 No. 3, September 1967 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Myocardial Contractile Force in Hemorrhagic Shock

Treatment With Phenoxybenzamine Hydrochloride, Metaproterenol Sulfate, or These Agents Combined

James R. Cook, MD; Theordore R. Sherrod, MD, PhD; Jack C. Cooley, MD

AMA Arch Surg. 1967;95(3):500-510.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

HEMORRHAGIC shock has been subject of concern to clinicians and has excited considerable interest among scores of investigators. The proper treatment of the patient in hemorrhagic shock constitutes a continuing discussion which has not been fully resolved. For many years, the accepted method of treating the severely hypotensive patient included a vasoconstrictor agent such as levarterenol or metaproteranol sulfate. These agents were effective in producing a marked elevation of blood pressure, but often did not result in the survival of the patient. In the mid-1950's such investigators as Nickerson1 and Lillehei2 suggested that vasodilating agents may offer a more physiologic approach to the treatment of patients in hemorrhagic shock. It was realized that effective tissue perfusion, rather than a normal blood pressure, was a more important factor in the survival of a shocked patient. This current study was conducted to evaluate myocardial performance when induced hemorrhagic shock is . . . [Full Text PDF of this Article]


Author Affiliations

Chicago; Urbana, Ill

From the Department of Pharmacology, University of Illinois College of Medicine, Chicago (Drs. Cook and Sherrod), and the Division of Surgery, Carle Clinic and Hospital, Urbana, Ill (Dr. Cooley). Doctor Cook is now at the Gargos Hospital, Balboa Heights, Panama Canal Zone.


Footnotes

Submitted for publication Feb 25 1967.

Read before the 24th annual meeting of the Central Surgical Association, Pittsburgh, Feb 25, 1967.

Reprint requests to 901 S Wolcott St, Chicago 60612 (Dr. Sherrod).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1967 American Medical Association. All Rights Reserved.